Data Support the Enrollment of Multiple Solid Tumor Cohorts in Trial NEW YORK and ANN ARBOR, November 7, 2017 — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the presentation of scientific data supporting the selection of tumor types for Lycera’s ongoing Phase 1/2a ARGON study of its novel… Read More

Cohort Expansion In Select Tumors of Interest NEW YORK and ANN ARBOR, Mich., Oct. 19, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the initiation of the Phase 2a portion of the company’s Phase 1/2a ARGON study of its novel immuno-oncology therapeutic candidate, LYC-55716 is a… Read More

Preliminary Findings from Phase 1/2a Trial Demonstrate LYC-55716 Was Well-Tolerated Durable Disease Stabilization Observed in Heavily Pretreated Patients NEW YORK and ANN ARBOR, Mich., September 11, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the first presentation of clinical findings from the initial three cohorts of… Read More

NEW YORK and ANN ARBOR, Mich., Mar. 13, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Pablo J. Cagnoni, M.D., has been elected to the Company’s Board of Directors, effective immediately. The Company also announced that Timothy M. Mayleben will step down from his position on… Read More

First-In-Class RORgamma Agonist to Begin Phase 1 – Dose Finding and Safety Assessment NEW YORK and ANN ARBOR, Mich., January 4, 2017 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 1/2a clinical trial of the Company’s novel immuno-oncology therapeutic candidate LYC-55716, in patients… Read More

First-In-Class Oral ATPase Modulator in Randomized Study Designed to Demonstrate Safety and Efficacy NEW YORK and ANN ARBOR, Mich., December 7, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 2 clinical trial of the Company’s lead therapeutic candidate, LYC-30937-Enteric Coated, in patients… Read More

NEW YORK and ANN ARBOR, Mich., Nov. 10, 2016 — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, today announced the expansion of its scientific advisory board (SAB) to include 11 renowned clinical researchers and scientists. The Company, which recently announced the initiation of its Phase 2 clinical trial of therapeutic… Read More

NEW YORK and ANN ARBOR, Mich., November 4, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the publication of new research findings for the Company’s most advanced cancer immunotherapy program: oral, selective RORgamma agonists.  RORgamma is a nuclear receptor transcription factor that serves as a master control… Read More

First-In-Class ATPase Modulator in Randomized Study Designed to Demonstrate Clinical Remission NEW YORK and ANN ARBOR, Mich., August 22, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initiation of a Phase 2 clinical trial of the Company’s lead clinical-stage candidate, LYC-30937-Enteric Coated, in patients with ulcerative… Read More

Dr. Toogood Recognized for His Contributions to Innovation in the Treatment of Metastatic Breast Cancer NEW YORK and ANN ARBOR, Mich., Aug. 3, 2016 /PRNewswire/ — Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today that Peter L. Toogood, Ph.D., Lycera’s Senior Vice President, Chemistry and Chemical Biology has received the… Read More